Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). No substantive Regulation FD disclosure provided in the supplied excerpt.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- No substantive Regulation FD disclosure provided in the supplied excerpt
- Excerpt contains only a Securities Act incorporation-by-reference disclaimer
Item 8.01 · Other Events
- Phase 1 enrolled 72 moderate-to-severe atopic dermatitis patients, including 35% with prior systemic therapy
- 200 mg twice-daily dosing produced EASI 75 responses in 50% after 28 days and 75% after 56 days
- EASI 90 reached 8% in cohort 3 and 25% in cohort 4; IGA 0/1 reached 25% and 33%, respectively
- Adverse events matched placebo at 41.7%, all Grade 1-2, with no serious events, dose changes, or significant laboratory abnormalities
- Responses persisted through 30-90-day drug-free follow-up without rebound or rescue medication, supporting potential differentiation but requiring larger trials
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.